Injective (INJ) is currently priced at $2.89, reflecting a 4.19% increase over the last 24 hours. The daily trading range has been tight, with a high of $2.97 and a low of $2.76, indicating a degree of price stability in the short term.

The trading volume stands at approximately 41.89 million, contributing to a volume-to-market cap ratio of 14.49%. This suggests a healthy level of trading activity relative to its market capitalization, indicating growing interest among investors.

Technical indicators show a mixed short-term outlook. The 8-day and 13-day Simple Moving Averages (SMAs) are declining at -1.74% and -0.91%, respectively, while the 21-day SMA is slightly positive at +0.29%. In contrast, the 55-day and 144-day SMAs have shown stronger bullish signals, both increasing by over 2%.

Relative Strength Index (RSI) readings reveal that INJ is in a neutral zone, with the 1-hour RSI at 54 and the 7-day RSI at 50. This indicates that while there is no immediate overbought or oversold condition, the price action could lead to further upward movement if momentum builds.

Fundamentally, the price is significantly below its all-time high of $52.62 reached in March 2024, suggesting substantial upside potential. Additionally, the positive price change over the last 30 days (+1.40%) juxtaposed with a negative 14-day change (-5.23%) indicates potential for recovery as market sentiment shifts.

Considering the current price action, technical indicators, and overall market sentiment, a Buy rating is warranted for Injective (INJ). The recent price movements and improving SMA indicators suggest that the asset may be poised for further gains, especially if it can sustain its current momentum.